Heron Therapeutics, Inc. (HRTX) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated January 9, 2026, serves as a Regulation FD disclosure for Heron Therapeutics, Inc. The filing announces the issuance of a press release containing preliminary financial results for the three months ended December 31, 2025, and the full year ended December 31, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1) but are not detailed in the body of this 8-K document.
Material Changes
No material changes or comparative financial data versus prior periods are disclosed within the text of this filing. The document solely references the availability of preliminary results for the most recent reporting periods.
Guidance, Outlook, and Risks
The filing does not include management commentary, forward-looking guidance, risk factors, or details on contingencies. It explicitly states that the information in Item 7.01 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated January 9, 2026) for actual preliminary financial figures for Q4 and Full Year 2025.
- Verify the company's cash position and burn rate, as these are critical for a biopharmaceutical entity but are not listed in this summary filing.
- Confirm if the preliminary results indicate any changes to the company's development timeline or capital requirements.
- Note that the information in this 8-K is not incorporated by reference into other SEC filings unless specifically cited.